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Abstract
Aim: To evaluate the relevance of endothelial-derived
apoptotic microparticles (EMPs) with inflammatory
cytokine outcomes in patients with ischaemic chronic heart
failure (CHF).
Methods: A total of 154 patients with moderate-to-severe
CHF were enrolled in the study. Flow cytometry analysis
was used for quantifying the number of EMPs. All-cause
mortality, CHF-related death, and CHD-readmission rates
were examined.
Results: During a median follow-up of 2.18 years, 21
participants died and 106 subjects were hospitalized
repetitively. Medians of circulating EMPs in survivor and
non-survivor patient cohorts were 0.286 n/mL (95% CI =
0.271-0.309 n/mL) and 0.673 n/mL (95% CI = 0.65-0.74 n/mL)
(P<0.001). There was a significantly lower concentration of
sRANKL, OPG, TNF-alpha, sFAS, and sFAS ligand in the
survivor patients when compared with those who met
composed endpoints. The sFAS/sFAS ligand ratio in the
non-survivor patient cohort was significantly higher than
in the survivor cohort (P<0.001). In multivariate model
EPMs, NYHA class, NT-pro-BNP, TNF-alpha, sFAS/sFAS
ligand ratio, and OPG remained statistically significant for
the cumulative endpoint: all-cause mortality, CHF-related
death, and CHF-related readmission.
Conclusion: Increased apoptotic circulating EMPs, OPG,
and FAS-sFAS ligand ratio independently predicted
cumulative survival in CHF patients.
Keywords endothelial-derived apoptotic microparticles,
inflammation, chronic heart failure, survival
1. Introduction
Chronic heart failure (CHF) is associated with an increased
risk of cardiovascular death [1]. Recent investigations
suggested that inflammation might play a pivotal role in
the pathogenesis of CHF through inducing endothelial
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dysfunction [2]. As part of this process, hyperproduction
of apoptotic endothelial-derived microparticles (EMPs) are
reflected in the severity of inflammation and endothelial
dysfunction, which is crucial for development CHF [3].
EMPs are defined as a very heterogeneous population of
submicronic vesicles that are released in response to cell
activation, injury, apoptosis or inflammation [4]. EMPs
represent an intercellular communication that leads to
realization of an atherothrombosis and proinflammatory
effect [5, 6]. Increased circulating EMPs are detectable in
cardiovascular and chronic inflammation, as well as
metabolic disorders (obesity, diabetes mellitus), immunity,
vascular calcification, osteoporosis, and bone remodelling
[7-9]. The main cytokines that regulate mobbing and
differentiation of EMPs are the receptor activator of nuclear
factor-κB ligand (RANKL) and its decoy receptor, osteo‐
protegerin (OPG), tumour necrosis factor alpha (TNF-
alpha), sFas, sFas ligand [10]. While EMPs are considered
to be a marker of endothelial dysfunction and tissue
remodelling [11], their role as an indicator of inflammatory
responses and probably as prognostic biomarkers in CHF
is still not clear. The aim of this study was to prospectively
evaluate the relevance of EMPs with inflammatory cyto‐
kines and outcomes in CHF patients.
2. Methods
2.1 Patient population under study
A total of 154 patients aged 48 to 62 years with ischaemic
symptomatic moderate-to-severe CHF were prospectively
enrolled in the study. The NYHA class of CHF was
determined according current clinical guideline at dis‐
charge from the hospital. All patients were haemodynam‐
ically stable and they have given their voluntary written
informed consent before participation in the study. Cumu‐
lative survival related to CHF and all-cause mortality was
examined within three years. Re admission reason was
defined by source document review, observation of the
admitted patient or physician interview.
2.2 Methods for visualization of coronary arteries
Multispiral computed tomography angiography and/or
angiographic study was performed for all patients prior to
study entry on SOMATOM Volume Zoom scanner (Sie‐
mens, Erlangen, Germany) with two detector rows. After
preliminary native scanning, non-ionic contrast Omnipa‐
que (Amersham Health, Ireland) was administered for the
optimal image of the coronary arteries [12]
2.3 Echocardiography and tissue Doppler imaging
Transthoracic B-mode echocardiography and tissue
Doppler imaging were performed using an ACUSON
scanner (Siemens, Germany). Left ventricular ejection
fraction (LVEF) was measured by modified Simpson’s
method [13, 14]. Peak systolic (Sm), early diastolic (Em),
and late diastolic (Аm) myocardial velocities were meas‐
ured in the mitral annulus area, followed by calculations of
the velocity of early diastolic left ventricular filling (E) to
Аm (Е/Аm) ratio and to Em (Е/Em) ratio.
2.4 Glomerular filtration rate calculation
Glomerular filtration rate (GFR) was calculated using the
CKD-EPI formula [15].
2.5 Biomarker determination
All biomarkers were determined at baseline without a
blinding procedure. To determine biological marker
concentrations, blood samples were drawn in the morning
(at 7-8 a.m.) into cooled silicone test tubes with EDTA.
Blood samples were assayed immediately after venepunc‐
ture according to the recommendations of the manufactur‐
er of the analytical technique used. They were centrifuged
upon permanent cooling at 6,000 rpm for 3 min. Plasma was
then refrigerated immediately and supernatant was stored
at -70оС. Circulating NT-pro-BNP level was measured by
immunoelectrochemoluminescent assay using sets by R&D
Systems (USA) on Elecsys 1010 analyser (Roche, Man‐
nheim, Germany). Serum concentrations of osteoproteger‐
in (OPG), sRANKL (serum receptor activator of nuclear
factor-kappa B ligand TNF-alpha), sFas, sFas ligand were
determined in duplicate with commercially available
enzyme-linked immunosorbent assay kits (Bender Med‐
Systems GmbH, Vienna, Austria). A total of 100 μl serum
sample was assayed in parallel to known standard concen‐
trations for each biological marker. The mean intra-assay
coefficients of variation were <10% in all cases. Concentra‐
tions of total cholesterol (TC) and cholesterol of high-
density lipoproteins (HDLP) were measured by a
fermentation method. The cholesterol concentration of
low-density lipoproteins (LDL-C) was calculated accord‐
ing to the Friedewald formula (1972).
Endothelial-derived apoptotic microparticles were defined
as EMPs positively labelled for CD31 and annexin V
(CD31+/annexin V+) after were determined by flow
cytofluorimetry by phycoerythrin (PE)-conjugated mono‐
clonal antibody against CD31 (BD Biosciences, USA)
followed by incubation with fluorescein isothiocyanate
(FITC)-conjugated annexin V (BD Biosciences, USA) per
HD-FACS (High-Definition Fluorescence Activated Cell
Sorter) methodology. We used EDTA as an anti-coagulant
for collection of the samples and centrifuged them within
15 min at 1600 g for 30 min at 20°C to pellet the cells. After
this the plasma containing the MPs was carefully aspirated,
collected, and incubated with 760 μL PBS/calcium buffer.
The samples were then analysed on a FC500 flow cytometer
(Beckman Coulter) after 400 μL annexin-V binding buffer
was added. For each sample, 500,000 events have been
analysed (Sigma, St Louis, MO, USA).
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2.6 Statistical analysis
Statistical analysis was performed using SPSS for Win‐
dows, Version 22 (SPSS Inc., Chicago, IL, USA). The data
were presented as mean (М) and error of mean (±m) or 95%
confidence interval (CI), median (Ме) and interquartile
range (IQR). To compare the main parameters of the patient
groups (subject to the type of distribution of the parameters
analysed), the two-tailed Student t-test or Mann-Whitney
U-test was used. To compare categorical variables between
groups, Chi2 test (χ2) and Fisher’s exact test were used. The
factors, which could be potentially associated with circu‐
lating EMPs, were determined by logistic regression
analysis. A receiver operation characteristic (ROC) curve
was constructed to identify the optimal balanced cut-off
points of the EMP number with the predicted value.
Finding the best cut-off point of EMPs from the ROC curve
was performed with a method based on choosing the value
that minimizes the Euclidean distance between ROC curve
and the upper left corner of obtained graph. Odds ratio
(OR) and 95% CI were calculated for all of the independent
predictors of survival of the patients. A calculated differ‐
ence of P<0.05 was considered significant.
3. Results
In a median follow-up of 2.18 years, 21 participants had
died and CHF-related death was defined in 18 patients.
Additionally, 106 subjects were hospitalized repetitively
due to advanced CHF (17 cases in non-survivors cohort and
89 cases in survivors cohort). Table 1 shows a general
characteristic of the patients included in the study. No
substantial demographic differences, as well as differences
in body mass index (BMI), glomerular filtration rate (GFR),
HbA1c, fasting blood glucose level, blood creatinine level,
total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C) and high-density lipoprotein cholesterol (HDL-
C), blood pressure (BP) and heart rate (HR), Е/Аm and
Е/Em, numerous of coronary vessels with atheroma were
found among non-survivor and survivor persons. The
subjects who experienced the composite endpoint demon‐
strated a higher frequency of hypertension, adherence to
smoking, more severe CHF classes, three- and multi-vessel
lesion, as well as higher levels of NT-pro-BNP, and lower







Subjects who did not
experience the composite
endpoint (n=34)
Age, years 57.20±6.70 59.50±7.30 57.32±6.15 59.10±6.70
Males, n (%) 12 (57.1%) 67 (50.3%) 64 (58.2%) 15 (44.2%)
Hypertension, n (%) 12 (57.1%) 61 (45.9%) 62 (56.4%) 13 (38.3%)**
Dyslipidaemia, n (%) 9 (42.8%) 52 (39.1%) 48 (43.6%) 13 (38.3%)
T2dm, n (%) 8 (38.1%) 45 (33.8%) 42 (38.2%) 11 (32.5%)
Adherence to smoking, n (%) 7 (33.3%) 24 (29.3%) 25 (22.7%) 6 (17.6%)**
II NYHA Class 6 (28.6%) 35 (26.3%) 26 (23.6%) 15 (44.1%)**
III NYHA Class 9 (42.8%) 65 (48.9%) 59 (53.4%) 15 (44.2%)**
IV NYHA Class 6 (28.6%) 33 (24.8%) 32 (29.1%) 7 (20.6%)**
BMI, kg/m2 23.7 (95% CI=22.5–27.3) 24.2 (95% CI=22.0–27.9) 23.9 (95% CI=20.7–25.9) 25.4 (95% CI=22.0–26.2)
GFR, mL/min/1.73 m2 82.1 (95% CI=69.9–93.1) 85.2 (95% CI=70.3–112.5) 81.5 (95% CI=71.3–94.7) 87.3 (95% CI=72.7–110.1)
HbA1c, % 6.3 (95% CI=4.4-9.0) 7.0 (95% CI=4.3-9.2) 6.6 (95% CI=4.6-8.3) 7.1 (95% CI=4.4-9.0)
Fasting blood glucose, mmol/L 4.80 (95% CI=3.6-8.5) 5.40 (95% CI=3.4-9.1) 4.92(95% CI=3.8-8.1) 5.36 (95% CI=3.7-8.3)
Creatinine, μmol/L 70.5 (95% CI=59.6–88.3) 74.9 (95% CI=65.1–90.3) 73.1 (95% CI=60.9–80.5) 79.2 (95% CI=68.8–91.2)
Total cholesterol, mmol/L 5.3 (95% CI=4.6-6.0) 5.0 (95% CI=4.2-5.8) 5.3 (95% CI=4.6-6.0) 5.0 (95% CI=4.2-5.8)
LDL-C, mmol/L 3.60 (95% CI =3.20–4.18) 3.02 (95% CI=2.80–3.90) 3.71 (95% CI =3.50–4.20) 3.10 (95% CI=2.90–4.10)
HDL-C, mmol/L 0.94 (95% CI = 0.92–1.06) 0.88 (95% CI = 0.82–0.97) 0.96 (95% CI = 0.93–1.05) 0.89 (95% CI = 0.84–0.99)
NT-pro-BNP, pg/mL 1533.6 (95% CI 644.5 – 2560.6) 1031.2 (95% CI 704.8 –1560.7)*
1977.2 (95% CI 984.7 –
2993.2)
1115.5 (95% CI 824.5 –
2060.1)**
Systolic BP, mm Hg 129±4 135±5 130±5 134±6
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Subjects who did not
experience the composite
endpoint (n=34)
Heart rate, beats per 1 min. 76±6 68±3 74±6 69±5
LVEF, % 42.80±2.76 55.40±3,80* 43.20±3.11 52.60±4,50**
Е/Аm, U 16.6±0.94 16.5±1.20 16.5±1.01 16.4±1.00
Е/Em, U 16.6±1.00 16.6±0.84 16.3±0.88 16.5±1.02
One-vessel lesion of coronary arteries, n (%) 5 (23.8%) 24 (18.0%) 15 (13.6%) 14 (41.2%)**
Two-vessel lesion of coronary arteries, n (%) 8 (38.1%) 54 (40.1%) 46 (41.8%) 16 (47.1%)
Three- and multi-vessel lesion, n (%) 8 (38.1%) 55 (41.4%) 49 (44.5%) 4 (11.8%)**
ACEI/ARAs, n (%) 21 (100%) 133 (100%) 110 (100%) 34 (100%)
Acetylsalicylic acid, n (%) 19 (90.5%) 121 (91.0%) 96 (87.3%) 34 (100%)
Other antiaggregants, n (%) 2 (9.5%) 12 (9.0%) 14 (12.7%) 0
Statins, n (%) 14 (66.7%) 80 (60.2%) 48 (43.6%) 13 (38.3%)
Metformin, n (%) 8 (38.1%) 45 (33.8%) 42 (38.2%) 11 (32.5%)
Loop diuretics, n (%) 18 (85.7%) 121 (91.0%) 110 (100%) 29 (85.3%)**
Mineralocorticoid receptor antagonists, n
(%) 9 (42.9%) 70 (52.6%) 45 (40.9%) 34 (100%)**
Note: * - statistical differences between parameters in surviving and non-surviving patients (P<0.05); * - statistical differences between parameters in the
patients who met and did not meet composite endpoints (P<0.05);
Abbreviations: CI – confidence interval; CAD – coronary artery disease, T2DM – type two diabetes mellitus, GFR - Glomerular filtration rate, HDL-C - high-
density lipoprotein cholesterol, LDL-C - low-density lipoprotein cholesterol, BP – blood pressure, BMI - body mass index, NYHA - New York Heart Association,
BNP – brain natriuretic peptide, LVEF - left ventricular ejection fraction, U – unit, Em - early diastolic myocardial velocity, Аm - late diastolic myocardial
velocity, E – peak velocity of early diastolic left ventricular filling, ACEI – angiotensin-converting enzyme inhibitor, ARAs – angiotensin-2 receptors antagonists.
Table 1. General characteristics of patients participating in the study
Incidence of type 2 diabetes mellitus in the patients of the
two cohorts was 38.1% and 33.8% (P=0.06). The level of
circulating NT-pro-BNP was statistically significantly
higher in the patients who died than in those who survived.
No substantial differences were found between the two
cohorts with regard to drug administration.
Medians of circulating EMPs in survivor and non-survivor
patient cohorts were 0.286 n/mL (95% CI = 0.271-0.309
n/mL) and 0.673 n/mL (95% CI = 0.65-0.74 n/mL) (P<0.001).
The number of circulating MPs was distributed into
quartiles (Q): Q1 (< 0.341 n/mL), Q2 (0.342-0.514 n/mL), Q3
(0.521-0.848 n/mL), and Q4 (> 0.850 n/mL). There was a
significantly lower concentration of sRANKL, OPG, TNF-
alpha, sFAS, and sFAS ligand in surviving patients when
compared with those who met composed endpoints (Table
2). The sFAS/sFAS ligand ratio in the non-survivor patient
cohort was significantly higher than in the survivor cohort
(P<0.001).
The data show that EMP number was positively associated
with NYHA class (r = 0.93, P = 0.001), sFAS/sFASl ratio (r =
0.88, P = 0.001), sFAS (r = 0.856, P = 0.001), TNF-alpha (r =
0.827, P = 0.001), OPG (r = 0.796, P = 0.001), sFASl (r = 0.589,
P = 0.001), sRANKL (r = 0.692, P = 0.001), NT-pro-BNP (r =
0.689, P = 0.001), T2DM (r = 0.402, P = 0.003), multi-vessel
lesion of coronary arteries (r = 0.362, P = 0.001), Е/Аm (r =
0.360, P = 0.001), and inversely associated with LVEF (r =
-0.496, P = 0.001), eGFR (r = -0.408, P = 0.003), and HDL
cholesterol (r = -0.221, P = 0.002). No significant association
between levels of circulating EMPs with fasting plasma
glucose, HbA1c, means systolic and diastolic BP, and
medications for both cohorts of the patients was found.
The optimum balance between the sensitivity and specif‐
icity cut-off point for EMP number in circulation was 0.514
n/mL (Figure 1). The area under the curve was 0.913 (95%
CI = 0.863-0.962), and sensitivity and specificity were 89.6%
and 69.7% respectively. The optimal balanced sensitivity
and specificity of EMP cut-off point level for other clinical
outcomes in the studied patient population are presented
in Table 3.
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Variables
Survived subjects Non-surviving subjects
P-value
Me CI Me CI
EMPs, n/mL 0.286 0.271-0.309 0.673 0.65-0.74 0.001
sRANKL, pg/mL 2045.90 1965.8-2876.1 2976.10 2553.1-31358.1 0.001
OPG, pg/mL 3725.9 2579.9-4871.9 5544.3 5306.4-5782.1 0.001
TNF-alpha, pg/mL 2.63 2.45 – 2.80 5.23 4.74 – 5.21 0.001
sFAS, ng/mL 2.96 2.75 – 3.17 5.17 4.90 – 5.47 0.001
sFASl, ng/mL 0.69 0.68 – 0.70 0.77 0.75 – 0.79 0.001
sFAS/sFASl ratio 4.22 3.96 – 4.49 6.7 6.37 – 7.02 0.001
Note: Statistics done as medians (Me) and 95% confidence intervals (CI), EMPs – endothelial-derived microparticles, TNF – tumour necrosis factor.
Table 2. Circulating levels of EMPs, TNF-alpha, sRANKL, OPG, sFAS, and sFAS ligand in both cohort patients
Cut-off point, n/mL Sensitivity, % Specificity, % AUC (95% CI) P-value
CHF-related death 0.514 99.3 56.2 0.906 (0.843-0.970) 0.001
CHF-related hospitalization 0.514 87.5 65.0 0.86 (0.796-0.924) 0.001
All-cause mortality 0.514 99.6 57.4 0.906 (0.846-0.965) 0.001
Note: AUC – area under curve, CI – confidence interval.
Table 3. The optimal balanced sensitivity and specificity of EMPs for clinical outcomes in the patient population studied. Results of receiver operation
characteristic analysis.
For all occasions the model was robust, and provided
significant results using the optimal cut-off point of EMPs.
Area Under the Curve
Test Result Variable(s): Endothelial‐derived micropaticles CD31+annexin V+
Area Std. Errora Asymptotic Sig.b Asymptotic 95% Confidence Interval
Lower Bound Upper Bound






Area Std. Errora Asymptotic Sig.b Asymptotic 95% Confidence Interval
Lower Bound Upper Bound




Figure 1. Reliability of the model included EMP number for cumulative
survival in the patient population of the study. Results of ROC analysis. The
figure shows the ratio of sensitivity and specificity for optimal predicted
number of EMPs.
A significant divergence of Kaplan-Meier survival curves
in patients with high quartiles of EMPs (numbers Q3 and
Q4) when compared with low quartiles of the biomarker
(Q1 and Q2) was found (Figure 2). The curve’s divergence
of event accumulation reached statistical significance at 50
weeks of the observation period (P<0.001).
P=0.001
NC
Note: Quartiles (Q) of EMPs: Q1 (< 0.341 n/mL), Q2 (0.342-0.514 n/mL), Q3
(0.521-0.848 n/mL), and Q4 (> 0.850 n/mL).
Figure 2. The divergence of Kaplan-Meier survival curves for patient cohorts
dependent on quartiles of EMPs
5Alexander E Berezin, Alexander A Kremzer and Yulia V Martovitskaya:
Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure – Relevance to Inflammatory Cytokines and
Outcomes
Univariate and multivariate logistic regression were used
to assess whether any combination of assays was able to
better discriminate between survivors and non-survivors.
In univariate logistic regression analysis, the main factors
independently related to cumulative endpoints were
EPMs, OPG, NT-pro-BNP, NYHA class, TNF-alpha, sFAS/
sFAS ligand ratio, decreased LVEF (less 45%), and T2DM
(Table 4). In multivariate model EPMs, NYHA class, NT-
pro-BNP, TNF-alpha, sFAS/sFAS ligand ratio, and OPG
remained statistically significant for the cumulative
endpoint: all-cause mortality, CHF-related death, and
CHF-related readmission.
Variables
All-cause mortality CHF-related death CHF-related readmission
OR 95% CI P OR 95% CI P OR 95% CI P
Univariate model
EMPs, per 0.225 n/mL 1.58 1.20–1.88 0.001 1.22 1.12–1.36 0.001 1.20 1.11 – 1.32 0.001
NYHA class 1.12 1.01–1.24 0.05 1.18 1.05–1.30 0.001 1.12 1.07 – 1.22 0.001
OPG, per 1030 pg/mL 1.46 1.12-1.92 0.001 1.28 1.10-1.37 0.001 1.14 1.09-1.19 0.002
TNF-alpha, per 2.3
pg/mL 1.10 1.03–1.17 0.016 1.12 1.02–1.19 0.012 1.16 1.10 – 1.26 0.001
sFAS/sFAS ligand ratio,
per 1.54 unit 1.12 1.06–1.20 0.001 1.14 1.08–1.22 0.001 1.15 1.12 – 1.19 0.001
NT-pro-BNP, per 540
pg/mL 1.09 1.02–1.16 0.002 1.42 1.22–1.73 0.006 1.44 1.28–1.67 0.002
LVEF less 45% 1.06 1.01–1.12 0.001 1.15 1.12–1.18 0.014 1.22 1.07–1.45 0.016
T2DM (present versus
absent) 1.05 1.01–1.11 0.001 1.03 0.93–1.10 0.32 1.04 0.97–1.06 0.42
Multivariate model
EMPs, per 0.225 n/mL 1.36 1.14–1.59 0.001 1.13 1.04–1.20 0.001 1.14 1.03 – 1.18 0.001
NYHA class 1.11 1.03–1.20 0.001 1.12 1.07–1.22 0.001 1.10 1.05 – 1.16 0.001
OPG, per 1030 pg/mL 1.25 1.10-1.42 0.001 1.13 1.08-1.20 0.002 1.11 1.05-1.17 0.001
TNF-alpha, per 2.3
pg/mL 1.09 1.04–1.15 0.002 1.05 1.00–1.11 0.001 1.10 1.04 – 1.15 0.001
sFAS/sFAS ligand ratio,
per 1.54 unit 1.06 1.02–1.15 0.001 1.08 1.04–1.13 0.001 1.10 1.06 – 1.17 0.001
NT-pro-BNP, per 540
pg/mL 1.04 1.01–1.07 0.001 1.10 1.05–1.17 0.001 1.22 1.15–1.34 0.001
LVEF less 45% 1.04 1.00–1.07 0.001 1.03 0.98–1.05 0.012 1.08 0.96–1.21 0.024
T2DM (present versus
absent) 1.02 0.96–1.04 0.001 1.01 0.92–1.04 0.032 1.04 0.97–1.06 0.42
Note: OR – odds ratio, CI – confidence interval; LVEF – left ventricular ejection fraction; BNP – brain natriuretic peptide; T2DM – type two diabetes mellitus;
OPG - osteoprotegerin.
Table 4. Predictors of three-year all-cause mortality, CHF-related death, and CHF-related readmission
Thus, we suggested that EMCs, OPG, FAS-sFAS ligand
ratio remained statistically significant predictors for
cumulative survival in CHF patients.
4. Discussion
The endothelium is one of the main targets of circulating
EMPs; hence, EMPs have been considered as biomarkers of
vascular injury, inflammation and stage of progression of
cardiovascular disease [17-19]. In fact, serum RANKL,
OPG, Fas ligand (FasL), and natriuretic peptides are well-
established mutually related biomarkers of CHF, reflecting
several faces of the pathogenesis of disease [20]. It is well
known that apoptosis or programmed cell death may
induce through bound FASl with its membrane receptor
and this process promotes impairing survival of endothe‐
lial cells, although solubilized form (sFasL) of FAS ligand
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loses its apoptotic activity after conversion by metallopro‐
teinases from membrane-associated FasL. It is also known
that a Fas-Fas ligand system is a representative pathway of
the apoptosis-signalling mechanism, activated by TNF-
alpha [21]. A recent study has revealed an association
between EMPs with cardiovascular outcomes [10]. In our
investigation a significant increase of EMP levels in the
circulation of ischaemic CHF patients who died was found
when compared with those who survived. Because endo‐
thelial cells express FasL constitutively and TNF-alpha
contributes to apoptosis through affecting the Fas-Fas
ligand system [22], we proposed that increasing EMP levels
in CHF patients may be related to TNF-alpha induced FAS-
sFAS ligands and OPG/sRANKL cooperation.
Recent studies showed OPG to be a member of the tumour
necrosis factor receptor superfamily and serum RANK/
RANKL have been identified as candidate mediators for
paracrine signalling in cell metabolism and extracellular
matrix regulation but have also been shown to modulate
dendritic cells and activated T cells, as well promoting B-
cell maturation and antibody response, which suggests a
role in both innate and adaptive immunity [23-25]. There‐
fore, serum RANKL and OPG as a RANKL inhibitor are
increasingly being investigated as markers of cardiovascu‐
lar risk, subclinical atherosclerosis, and cardiac remodel‐
ling and vascular calcification [26-32]. However, the role of
the sRANKL/OPG complex in the maintenance of repara‐
tive repair potency in people with CHF shows to be very
intriguing, while clinical data are limited.
We suggested that a mismatch between apoptotic process‐
es and endothelial cell survival, indirectly determined
through the calculation of the FAS/-sFAS ligand ratio and
sRANKL/OPG complex, was more profound in subjects
who did than in those who survived. Thus, we confirmed
that pro-inflammatory activation is dramatically increased
in CHF subjects at a high risk of death, it probably asso‐
ciates with endothelial dysfunction, and EMP level might
reflect the severity of these disorders. We also noted that
CHF patients with low levels of EMPs have demonstrated
a superior chance of survival when compared with subjects
with a high level of EMPs. Using this data we found that
increased EMP number, higher than 0.514 n/mL, independ‐
ently predicted all-cause mortality, CHF-related death, and
CHF-related readmission within the observation period. A
multivariable prediction model has shown a high decre‐
mented potential of EMP alone in CHF patients in the three
years after study entry. These findings suggest that
increased EMP number might improve the predictive value
of a contemporary model of CHF based on clinical per‐
formances and NT-pro-BNP measurements. In this study,
levels of EMCs, OPG, FAS-sFAS ligand ratio were sufficient
to predict long-term changes in cumulative survival.
In conclusion, increased apoptotic circulating EMP, OPG,
and FAS-sFAS ligand ratio independently predicted
cumulative survival in CHF patients.
5. Compliance with ethical research standards
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Study Restrictions: This study has some restrictions. The
authors believe that a greater cohort of patients with more
incidences  detected would be  desirable  to  improve the
power of  the study.  Because the main limitation of the
study was its small size and low frequency of events, we
think  that  this  is  the  reason  for  the  low  specificity  of
EMPs. It should be emphasized that while EMPs have a
high diagnostic  potential  as biomarkers in cardiovascu‐
lar  diseases  and  cancer,  due  to  current  technological
limitations in the purification of EMPs and an absence of
standardized methods of detection the role of EMPs has
become controversial. We think that this is a reason for
the low specificity of EMPs and this may negatively bias
the ROC curve.  The authors suppose that these restric‐
tions might have no significant impact on the study data
interpretation.
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